Kai‐Keen Shiu

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · New England Journal of Medicine · 2020 · 2.8K citations · Full text

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim et al. · The Lancet Oncology · 2022 · 818 citations · Full text

Medicine, Immunology, Pathology +9

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.

Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · Journal of Clinical Oncology · 2020 · 196 citations

Immunology, Pathology, Lba4 Background +16

Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers

Daniel Wetterskog, M. Ángeles López‐García, Maryou B. Lambros et al. · The Journal of Pathology · 2011 · 164 citations

Distinct Subgroup, Breast Adccs, Cancer Pathology +17